Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database.
about
Chinese herbal medicines for treating osteoporosisComparative statistical analysis of osteoporosis treatment based on Hungarian claims data and interpretation of the results in respect to cost-effectiveness.Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISAAlendronate soluble solution: a higher adherence rate in the treatment of osteoporosis.Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study.Long-term persistence with anti-osteoporosis drugs after fracture.Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United StatesOne and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study.A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary.Localization of Minodronate in Mouse Femora Through Isotope MicroscopyReproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ).Minodronate for the treatment of osteoporosis.
P2860
Q24198040-54740B66-1707-405E-A941-6554E0BC7505Q30819137-B0DD7E3D-5724-45AF-8728-DC4B44B4DA3DQ30988951-07B9BF1A-8718-4917-A526-B9A4D717C3ECQ34230314-FA807343-4FF1-477C-8AB5-3F8C332C628DQ34966547-4176E235-8D45-4D95-9A21-C52234AD88D1Q35707347-5FD80DFE-E9C4-4435-9D49-B6E93E5E055CQ35747751-3214B221-7445-4BBC-A2EF-5637EBDE691BQ37670574-C11726B1-BD97-4633-A049-C2F75A31398EQ38676331-3E7F2DCD-5C9F-4C3B-89EC-2C7B61F9EDC5Q39264339-EC0352DE-9112-4FE6-A034-50E69140F521Q40065539-BB6A10B3-0ED2-4B8F-AF63-4566CB4283CDQ40189823-08BD52BF-66E9-4368-8B51-D6655B4465C2Q41648438-D3A22E06-E93F-4A04-A317-1076B7AB1FF9Q55041856-940ACEDB-CC8C-400B-A42C-82B98DBFA23CQ55077666-40F5B201-B22F-4F7F-A701-467136645C08
P2860
Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Persistence at 1 year of oral ...... ive health insurance database.
@en
Persistence at 1 year of oral ...... ive health insurance database.
@nl
type
label
Persistence at 1 year of oral ...... ive health insurance database.
@en
Persistence at 1 year of oral ...... ive health insurance database.
@nl
prefLabel
Persistence at 1 year of oral ...... ive health insurance database.
@en
Persistence at 1 year of oral ...... ive health insurance database.
@nl
P2093
P356
P1476
Persistence at 1 year of oral ...... sive health insurance database
@en
P2093
Cyrille B Confavreux
Roland D Chapurlat
Valérie Tainturier
Véronique Ambrosi
P304
P356
10.1530/EJE-11-0959
P577
2012-01-18T00:00:00Z